Insider Selling: Artivion (NYSE:AORT) Insider Sells $105,847.68 in Stock

Artivion, Inc. (NYSE:AORT) insider John Davis sold 2,784 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $38.02, for a total value of $105,847.68. Following the completion of the transaction, the insider directly owned 206,522 shares in the company, valued at approximately $7,851,966.44. This represents a 1.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Artivion Stock Performance

NYSE:AORT opened at $37.87 on Friday. The stock has a 50-day simple moving average of $41.24 and a two-hundred day simple moving average of $42.88. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.62 and a current ratio of 3.53. Artivion, Inc. has a 52-week low of $21.97 and a 52-week high of $48.25. The firm has a market capitalization of $1.81 billion, a PE ratio of 189.36 and a beta of 1.60.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Thursday, February 12th. The company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.03. The firm had revenue of $118.30 million for the quarter, compared to analysts’ expectations of $116.42 million. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The firm’s revenue was up 19.2% on a year-over-year basis. Analysts forecast that Artivion, Inc. will post 0.37 EPS for the current year.

Wall Street Analyst Weigh In

AORT has been the topic of several recent analyst reports. Stifel Nicolaus set a $55.00 price objective on shares of Artivion in a research report on Thursday. Weiss Ratings raised Artivion from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, February 20th. Oppenheimer restated an “outperform” rating and issued a $50.00 price objective on shares of Artivion in a research report on Friday, November 7th. Citizens Jmp lifted their target price on Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research note on Friday, November 7th. Finally, Canaccord Genuity Group dropped their price target on Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, February 13th. Six analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Artivion has an average rating of “Moderate Buy” and an average target price of $50.47.

Key Artivion News

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Quarterly results beat expectations (EPS and revenue) and showed ~19% YoY revenue growth, supporting the growth narrative and analyst conviction. MarketBeat – Artivion Earnings Summary
• Positive Sentiment: Management will present at the Oppenheimer Healthcare MedTech & Services Conference — a near‑term event where guidance, commercialization updates or product milestones could be disclosed and re‑ignite buy‑side interest. Artivion to Participate in Oppenheimer Conference
• Positive Sentiment: Large institutional buying (notably Invesco’s sizable Q4 add and other funds increasing exposure) can provide steadier bid support and signals professional investor confidence. MarketBeat – Institutional Activity
• Neutral Sentiment: Analyst coverage remains constructive (consensus “Moderate Buy” with elevated price targets), which helps sentiment but may already be priced in. MarketBeat – Analyst Ratings
• Neutral Sentiment: Industry pieces highlight portfolio expansion and relative EPS performance on the NYSE Composite — useful narrative fuel but not an immediate catalyst. Kalkine – Portfolio Expansion Article
• Negative Sentiment: Clustered insider selling March 2–4: CEO James Mackin sold 17,887 shares (~$676k), EVP Lance Berry sold ~6,316 shares (~$238k), other senior execs (SVPs, CAO Amy Horton and others) sold multiple tranches. Markets often interpret concentrated senior‑level sales as a negative near‑term signal despite insiders retaining large stakes. See filings and coverage. SEC Form 4 – Mackin Benzinga – CCO Trade Benzinga – Lance Berry Sale

Hedge Funds Weigh In On Artivion

Several institutional investors have recently added to or reduced their stakes in the company. Summit Partners Public Asset Management LLC bought a new stake in Artivion in the 4th quarter worth approximately $39,401,000. Invesco Ltd. boosted its position in shares of Artivion by 211.9% during the 4th quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock valued at $50,228,000 after acquiring an additional 748,119 shares during the last quarter. Champlain Investment Partners LLC purchased a new position in shares of Artivion in the third quarter valued at $17,912,000. Goldman Sachs Group Inc. increased its position in Artivion by 144.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 537,375 shares of the company’s stock worth $24,510,000 after purchasing an additional 317,518 shares during the last quarter. Finally, Two Sigma Investments LP increased its position in Artivion by 235.5% in the third quarter. Two Sigma Investments LP now owns 446,535 shares of the company’s stock worth $18,906,000 after purchasing an additional 313,446 shares during the last quarter. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.